Turning Point Therapeutics Inc

NASDAQ:TPTX  
112.20
+9.11 (+8.84%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)5.87B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$17.5 Million
Adjusted EPS-$0.59
See more estimates
10-Day MA$114.72
50-Day MA$125.51
200-Day MA$94.07
See more pivots

Turning Point Therapeutics, Inc. Stock, NASDAQ:TPTX

10628 Science Center Drive, Suite 200, San Diego, California 92121
United States of America
Phone: +1.858.926.5251
Number of Employees: 95

Description

Turning Point Therapeutics, Inc. engages in the discovery and development of precision medicines for cancer and other diseases. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by J. Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA.